Lantern Pharma Inc. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Lantern Pharma Inc. (LTRN) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 3.72 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-14
- Lantern Pharma Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 1.50M shares, a 14.45% increase year-over-year.
- Lantern Pharma Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-03-31 was 1.31M shares, a 13.25% increase year-over-year.
- Lantern Pharma Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-03-31 was 1.16M shares, a 8.98% decline year-over-year.
- Lantern Pharma Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2023-03-31 was 1.27M shares, a 19.11% increase year-over-year.
- Lantern Pharma Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 1.31M shares, a 0.73% decline from fiscal 2024.
- Lantern Pharma Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 1.32M shares, a 3.66% increase from fiscal 2023.
- Lantern Pharma Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 1.27M shares, a 4.41% increase from fiscal 2022.
- Lantern Pharma Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 1.22M shares, a 4.38% increase from fiscal 2021.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month |
|---|---|---|---|---|
| 2026-06-30 | 3.72M shares 10-Q · filed 2026-08-14 | |||
| 2026-03-31 | 1.50M shares 10-Q · filed 2026-05-15 | |||
| 2025-12-31 | 1.31M shares 10-K · filed 2026-03-30 | |||
| 2025-09-30 | 1.22M shares 10-Q · filed 2025-11-12 | |||
| 2025-06-30 | 1.24M shares 10-Q · filed 2026-08-14 | |||
| 2025-03-31 | 1.31M shares 10-Q · filed 2026-05-15 | |||
| 2024-12-31 | 1.32M shares 10-K · filed 2026-03-30 | |||
| 2024-09-30 | 1.36M shares 10-Q · filed 2025-11-12 | |||
| 2024-06-30 | 1.15M shares 10-Q · filed 2025-08-13 | |||
| 2024-03-31 | 1.16M shares 10-Q · filed 2025-05-15 | |||
| 2023-12-31 | 1.27M shares 10-K · filed 2025-03-27 | |||
| 2023-09-30 | 1.24M shares 10-Q · filed 2024-11-07 | |||
| 2023-06-30 | 1.27M shares 10-Q · filed 2024-08-08 | |||
| 2023-03-31 | 1.27M shares 10-Q · filed 2024-05-09 | |||
| 2022-12-31 | 1.22M shares 10-K · filed 2024-03-18 | |||
| 2022-09-30 | 1.18M shares 10-Q · filed 2023-11-08 | |||
| 2022-06-30 | 1.12M shares 10-Q · filed 2023-08-09 | |||
| 2022-03-31 | 1.07M shares 10-Q · filed 2023-05-09 | |||
| 2021-12-31 | 1.16M shares 10-K · filed 2023-03-20 | |||
| 2021-09-30 | 1.10M shares 10-Q · filed 2022-11-07 | |||
| 2021-06-30 | 1.13M shares 10-Q · filed 2022-08-08 | |||
| 2020-12-31 | 1.16M shares 10-K · filed 2021-03-10 | |||
| 2020-09-30 | 1.15M shares 10-Q · filed 2020-10-29 | |||
| 2019-12-31 | 3.31M shares 10-K · filed 2021-03-10 | |||
| 2019-09-30 | 3.34M shares 10-Q · filed 2020-10-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |